New Recruiting Trial: Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
WHY IT MATTERS
This trial is the first to test asciminib specifically in pediatric patients with Ph+ CML-CP, potentially offering a new treatment option for children who may have limited alternatives or resistance to current therapies.
Novartis is testing a drug called asciminib in children who have a type of blood cancer called chronic myeloid leukemia (CML) that has a specific genetic change called the Philadelphia chromosome. This is a Phase 2 trial, which means researchers are checking if the drug works well and is safe in this younger age group. The study is now accepting patients and is expected to start in May 2026.
NCT ID: NCT07354074 Title: Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Status: RECRUITING Phase: PHASE2 Sponsor: Novartis Pharmaceuticals Start date: 2026-05-04 URL: https://clinicaltrials.gov/study/NCT07354074 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If your child has Ph+ CML-CP, contact your oncologist immediately to discuss eligibility for this trial or visit clinicaltrials.gov/study/NCT07354074 to find participating sites near you.